Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zentalis Pharmaceuticals Inc (ZNTL)

Zentalis Pharmaceuticals Inc (ZNTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 101,151
  • Shares Outstanding, K 72,251
  • Annual Sales, $ 67,430 K
  • Annual Income, $ -165,840 K
  • EBIT $ -162 M
  • EBITDA $ -165 M
  • 60-Month Beta 1.75
  • Price/Sales 1.48
  • Price/Cash Flow N/A
  • Price/Book 0.39

Options Overview Details

View History
  • Implied Volatility 257.52% (+5.84%)
  • Historical Volatility 58.26%
  • IV Percentile 61%
  • IV Rank 25.44%
  • IV High 686.04% on 04/08/25
  • IV Low 111.34% on 06/11/25
  • Expected Move (DTE 14) 0.0765 (5.50%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 20
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 1,443
  • Open Int (30-Day) 1,433
  • Expected Range 1.3135 to 1.4665

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.41
  • Number of Estimates 6
  • High Estimate -0.31
  • Low Estimate -0.53
  • Prior Year -0.66
  • Growth Rate Est. (year over year) +37.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2120 +14.69%
on 11/07/25
1.4600 -4.79%
on 11/28/25
+0.0500 (+3.73%)
since 11/05/25
3-Month
1.2120 +14.69%
on 11/07/25
1.8400 -24.46%
on 10/10/25
-0.3600 (-20.57%)
since 09/05/25
52-Week
1.0100 +37.62%
on 04/09/25
4.0000 -65.25%
on 12/09/24
-1.9500 (-58.38%)
since 12/05/24

Most Recent Stories

More News
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval,...

ZNTL : 1.3900 (-0.71%)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients...

ZNTL : 1.3900 (-0.71%)
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients...

ZNTL : 1.3900 (-0.71%)
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients...

ZNTL : 1.3900 (-0.71%)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1...

ZNTL : 1.3900 (-0.71%)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1...

ZNTL : 1.3900 (-0.71%)
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1...

ZNTL : 1.3900 (-0.71%)
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

SAN DIEGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1...

ZNTL : 1.3900 (-0.71%)
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval,...

ZNTL : 1.3900 (-0.71%)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZNTL : 1.3900 (-0.71%)

Business Summary

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative...

See More

Key Turning Points

3rd Resistance Point 1.4390
2nd Resistance Point 1.4292
1st Resistance Point 1.4096
Last Price 1.3900
1st Support Level 1.3802
2nd Support Level 1.3704
3rd Support Level 1.3508

See More

52-Week High 4.0000
Fibonacci 61.8% 2.8578
Fibonacci 50% 2.5050
Fibonacci 38.2% 2.1522
Last Price 1.3900
52-Week Low 1.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar